secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001641172-25-016014
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine to host R&D event July 9, 2025 on LPCN 1154 for postpartum depression; Phase 3 data Q2 2026
--------------------------------------------------------------------------------

- Virtual R&D investor event on July 9, 2025 at 11 AM ET to discuss LPCN 1154 (BRLIZIO) for postpartum depression (PPD).
- Phase 3 registrational study recently initiated; top-line data expected in Q2 2026.
- Event features Dr. Kristina Deligiannidis; includes clinical, regulatory, and development updates with Q&A.
- LPCN 1154 is an oral brexanolone formulation targeting rapid symptom relief with 48-hour outpatient treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225016014/0001641172-25-016014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225016014/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer